Calcitonin gene-related peptide receptor antagonist

Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drugs that act as antagonists of the calcitonin gene-related peptide receptor (CGRPR).

CGRPR antagonists are under investigation as potential antimigraine agents and also in the context of osteoarthritis.[1]

Examples

TEV-48125 is not a Calcitonin gene-related peptide receptor antagonist but a monoclonal antibody targeting CGRP .[3][4] Most experimental CGRP inhibitors are monoclonal antibodies[5] given by monthly injections.[5]

Clinical trials

In June 2015 Phase 2 clinical trial data for three different anti-CGRP drugs ( Amgen (AMG 334), Teva Pharmaceuticals (TEV-48125), and Eli Lilly & Co (LY2951742)) were presented at the American Headache Society's (AHS) annual meeting.[5]

In March 2016 Alder reported phase IIb clinical trial data for its ALD403.[6]

By April 2016, Alder, Amgen and Teva had initiated phase III trials.[7]

References

  1. ↑ Nakasa, T; Ishikawa, M; Takada, T; Miyaki, S; Ochi, M (2015). "Attenuation of cartilage degeneration by calcitonin gene-related paptide receptor antagonist via inhibition of subchondral bone sclerosis in osteoarthritis mice". Journal of Orthopaedic Research: n/a. doi:10.1002/jor.23132. PMID 26686833.
  2. ↑ Tfelt-Hansen, P; Olesen, J (Apr 2011). "Possible site of action of CGRP antagonists in migraine.". Cephalalgia: an international journal of headache. 31 (6): 748–50. doi:10.1177/0333102411398403. PMID 21383046.
  3. ↑ H. Spreitzer (29 February 2016). "Neue Wirkstoffe – TEV-48125". Österreichische Apothekerzeitung (in German) (5/2016): 12.
  4. ↑ Walter, S; Bigal, M. E. (2015). "TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine". Current Pain and Headache Reports. 19 (3): 6. doi:10.1007/s11916-015-0476-1. PMID 25754596.
  5. 1 2 3 New Data on CGRP Monoclonal Antibodies for Migraine Prevention. June 2015
  6. ↑ Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine. March 2016
  7. ↑ Can Alder Beat Teva And Amgen In Treating Migraines? Will Positive Phase III Data Help Keryx's Auryxia Receive Approval For An Expanded Indication? April 2016


This article is issued from Wikipedia - version of the 7/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.